Industry Pharmaceutical Products NanoXrayTM Number of employees 31 (2011) | Key people Laurent Lévy( CEO) Website www.nanobiotix.com Founded 2003 | |
 | ||
Stock price NANO (EPA) € 16.30 +0.39 (+2.45%)20 Mar, 5:35 PM GMT+1 - Disclaimer Profiles | ||
Nanobiotix ceo we re not like other biotechs
Nanobiotix is a nanomedicine company dedicated to the development of new treatments for cancer based on the combined application of nanotechnologies and biotechnologies. The company is based in Paris.
Contents
- Nanobiotix ceo we re not like other biotechs
- Augmentation de capital pour nanobiotix
- History
- Corporate structure
- Therapeutics
- Research and development
- References
Augmentation de capital pour nanobiotix
History
Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 and has been primarily funded by leading European venture capital firms (Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes, CIC Vizille; Masseran Gestion-CGE).
Corporate structure
Therapeutics
Nanobiotix has developed a new class of therapeutics based on nanoparticles, NanoXray™ therapeutics. They consist of inert nanoparticles designed to enter tumor cells. Upon activation by a standard dose of radiation, they release a tremendous amount of energy that destroys cancer cells, whilst the surrounding healthy tissues are preserved and receive the same dose of radiation as in standard radiotherapy.
Research and development
Nanobiotix has already won 10 public and private awards and owns 9 original umbrella patents.
Pipeline: